From: Pradeep Rajan [pradeep.rajan Ex. 6 Personal Privacy (PP)

Sent: 9/19/2017 3:18:37 PM

To: Lehmann, Geniece [Lehmann.Geniece@epa.gov]; Trgovcich, Joanne [Joanne.Trgovcich@icf.com]; Pamela Lein

[pjlein@ucdavis.edu]; sagiv@berkeley.edu

CC: Carlson, Laura [Carlson.Laura@epa.gov]
Subject: Revised PECO for neurological effects

Attachments: PECO Table Neurological Effects 9 19 17.docx; PECO Table Neurological Effects 9 19 17 trk chng.docx

Hi Geniece,

Please find attached our revised PECO for neurological effects in two versions: one version includes track changes to denote where we made edits to the prior version you reviewed, and the other version has all track changes accepted.

Ex. 5 Deliberative Process (DP)

Thank you,

Pradeep

Pradeep Rajan, ScD President


Pradeep Rajan LLC phone: 919-888-1130

pradeep.rajan@pradeeprajanllc.com

On 9/1/2017 12:03 PM, Lehmann, Geniece wrote:

Hi All,

Ex. 5 Deliberative Process (DP)



Phone: 919-541-2289 Fax: 919-541-0245

Notice (If This Communication Regards a Contract): Nothing in this message shall be construed as a change to the price, schedule, or terms and conditions of the contract. If the receiver does construe it otherwise, please notify me or the contracting officer immediately so that proper contract action can be initiated.

From: Trgovcich, Joanne [mailto:Joanne.Trgovcich@icf.com]

Sent: Friday, September 01, 2017 10:20 AM

To: Pamela Lein <pjlein@ucdavis.edu>; pradeep.rajan@pradeeprajanllc.com; sagiv@berkeley.edu

Cc: Lehmann, Geniece < Lehmann. Geniece@epa.gov>

Subject: RE: revised PECOs


Hi All,

Thank you all for this update. I've copied Geniece on this message because Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Regards, Joanne

Ex. 5 Deliberative Process (DP)



Subject: RE: revised PECOs

Hi Pradeep:

Thanks for working on this again – just completed Day 4 of our 5-day drive back across the country from Ithaca, NY to Davis, CA. I am a bit wiped out after driving for 8 hours so perhaps my comments reflect that, but as I replied in the document itse Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Best,

Pam

From: Pradeep Rajan [mailto:pradeep.rajan (Ex. 6 Personal Privacy (PP)]

Sent: Thursday, August 31, 2017 2:12 PM

To: Pamela J Lein <pjlein@ucdavis.edu>; sagiv@berkeley.edu

Subject: Re: revised PECOs

Hi Pam and Sharon:

Ex. 5 Deliberative Process (DP)

If you can let me know your thoughts on this version along with any edits by tomorrow afternoon (4PM EST) I'll make any final edits and submit to Geniece.

Thanks!

Pradeep

Pradeep Rajan, ScD President Pradeep Rajan LLC phone: 919-888-1130

pradeep.rajan@ Ex. 6 Personal Privacy (PP) On 8/29/2017 6:45 AM, Pamela J Lein wrote:

Hi Joanne:

We all spoke on the phone about this last week – I sent my input to Sharon and Pradeep to consider in the context of the combined human/animal PECO statement. Pradeep was planning to modify a few things, and then send the document to you and Geniece.

Attached is the latest version I have with my input.

Pam

From: Trgovcich, Joanne [mailto:Joanne.Trgovcich@icf.com]

Sent: Monday, August 28, 2017 8:11 AM

To: Pamela J Lein cpilein@ucdavis.edu>; Sharon Sagiv <sagiv@berkeley.edu>; Pradeep

Hi All,

I hope this message finds you well. I am writing to ask when you may be returning the revised PECO statements for the neurological outcomes as we have past the original deadlines outlined in the message from Geniece below. I know that Sharon and Pradeep are close for the human outcomes. Pam could you provide a date when you will finish the animal outcomes?

Thanks, Joanne

JOANNE TRGOVCICH | Senior Technical Specialist | +919-293-1661 direct | mailto:joanne.trgovcich@icf.com | icf.com | ICF | 2635 Meridian Parkway, Suite 200, Durham, NC 27713 USA

Learn how ICF makes big things possible for its clients.

From: Lehmann, Geniece [mailto:Lehmann.Geniece@epa.gov]

Sent: Monday, August 07, 2017 11:03 AM

To: Wright, Michael < Wright. Michael @epa.gov>; Muralidharan, Revathi

<Revathi.Muralidharan@icf.com>; Taylor, MicheleM <taylor, michelem@epa.gov>;

Mudipalli, Anuradha < Mudipalli. Anu@epa.gov>; Carlson, Laura

<<u>Carlson.Laura@epa.gov</u>>; Arzuaga, Xabier <<u>Arzuaga.Xabier@epa.gov</u>>; Luke, April

<Luke.April@epa.gov>; Rutigliano, Marian <Rutigliano.Marian@epa.gov>; Li, Jenny

<<u>Li.Jenny@epa.gov</u>>; Lobdell, Danelle <<u>Lobdell.Danelle@epa.gov</u>>; Trgovcich, Joanne

<Joanne.Trgovcich@icf.com>; Burch, Dave <dave.burch@icf.com>; Pamela Lein

<pjlein@ucdavis.edu>; larry-robertson@uiowa.edu; sagiv@berkeley.edu;

meekerj@umich.edu; Michael Bloom <mbloom@albany.edu>; a.sergeev01 (Ex. 6 Personal Privacy (PP)

MToborek@med.miami.edu; Pam Factor-Litvak <prf1@cumc.columbia.edu>; Martina

Velichkovska <mxv567@miami.edu>; akeating@iastate.edu; Selgrade, MaryJane

<MaryJane.Selgrade@icf.com>; Yost, Erin <Yost.Erin@epa.gov>; Persad, Amanda

<Persad.Amanda@epa.gov>; Pardo, Larissa <Pardo.Larissa@epa.gov>;

Todd_Jusko@URMC.Rochester.edu; pradeep.rajan@| Ex. 6 Personal Privacy (PP)

Subject: PCB Team Status Update

Please find your name below and either complete the assigned task(s) or let me know when you plan to do so. Updated versions of the "compiled outcome determinations" document (v5) and the draft IAP (v2) are attached.

Review my revisions/responses to your comments on the draft IAP (v2) (attached to this email) (8/11):

- (1) <!--[if !supportLists]--><![endif]-->Alex and Michal
- (2) <!--[if !supportLists]--><![endif]-->**Michael**
- (3) <!--[if !supportLists]--><![endif]-->Laura
- (4) <!--[if !supportLists]--><![endif]-->Erin and Xabier

Review draft IAP (attached to this email):

(1) <!--[if !supportLists]--><![endif]-->**April** - endocrine effect section (8/11)

- (2) <!--[if !supportLists]--><![endif]-->Larissa and MaryJane hematological effect section (8/11)
- (3) <!--[if !supportLists]--><![endif]-->Larry hepatic effect section (8/11)
- (4) <!--[if !supportLists]--><![endif]-->Marian metabolic effect section (8/14)
- (5) <!--[if !supportLists]--><![endif]-->Pam Factor-Litvak reproductive effect section (8/7)

Submit draft PECO statement or revised draft PECO statement:

- (1) <!--[if !supportLists]--><![endif]-->Pam Lein neurological effects in animals (8/7)
- (2) <!--[if !supportLists]--><![endif]-->Pradeep, Sharon, and Pam Lein work together and come to decision about which outcomes to move forward for systematic review; propose a due date for this decision by 8/11

Edit/update "compiled outcome determinations" document (attached to this email):

- (1) <!--[if !supportLists]--><![endif]-->**Todd** and **MaryJane** work together and come to decision about the remaining outcomes in question; propose a due date for this decision by 8/11
- (2) <!--[if !supportLists]--><![endif]-->Pam Factor-Litvak (8/7)

Submit plan for dermal/ocular effect section:

(1) <!--[if !supportLists]--><![endif]-->**Marian** (8/14)

Submit updated literature inventory(ies):

- (1) <!--[if !supportLists]--><![endif]-->Aileen (ASAP*): developmental effects in animals; provide status update, including % completed and projected due date by 8/11
- (2) <!--[if !supportLists]--><![endif]-->Larissa: renal effects in humans (8/17) & hematological effects in humans (9/3)

Thanks, Geniece

Geniece M. Lehmann, Ph.D.
Toxicologist
National Center for Environmental Assessment
Office of Research & Development
U.S. Environmental Protection Agency, B243-01
RTP, NC 27711

Phone: 919-541-2289 Fax: 919-541-0245

Notice (If This Communication Regards a Contract): Nothing in this message shall be construed as a change to the price, schedule, or terms and conditions of the contract. If the receiver does construe it otherwise, please notify me or the contracting officer immediately so that proper contract action can be initiated.